Search
Now showing items 1-2 of 2
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
(Elsevier, 2022-04-20)
Background WHO guidelines recommend dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs)
for second-line HIV therapy, with NRTI switching from first-line tenofovir to zidovudine. We aimed to ...
Longitudinal patients’ cohorts for impactful research and HIV care at the Infectious Diseases Institute
(2022)
Introduction
Observational studies provide important evidence supporting the feasibility and effectiveness of health interventions. The 20-year-old Infectious Diseases Institute (IDI) established to respond to infectious ...